Innova Captab (Mid Cap - High Growth) Share Target 2025, 2026 To 2035
|
Innova Captab Limited |
|||
|
Price: ₹1,068.85 (+6.57%) | ||
| 52 Week Low: ₹421.35 52 Week High: ₹1,260.00 |
|||
| Market Capital: 5,506.75 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Innova Captab Share Price Target For 2025
- 1.1.1: Innova Captab Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Innova Captab Share Price Target For 2026
- 1.2.1: Innova Captab Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Innova Captab Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Innova Captab Brief Company Overview
- 4: Innova Captab Financial Performance
- 4.0.1: Is Innova Captab A Good Buy For Long Term?
Innova Captab, a Mid Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 94.0% returns in 1-year showing 12.5% quarterly revenue growth with 10.0% profit margin, making it a High Growth stock.
To predict the Innova Captab's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Innova Captab Share Price Target For 2025
The line chart displays the monthly closing prices of Innova Captab with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Innova Captab shares in 2025, see the table below.
Innova Captab Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1250.15 (+16.96%) | Price Action: 07 Jan 2025 High |
| 2025 Target 2 | 1215.0 (+13.67%) | Price Action: 03 Jan 2025 High |
| 2025 Target 1 | 1202.15 (+12.47%) | Price Action: 07 Jan 2025 Low |
| Current Price | 1068.85 | Innova Captab's share price as of 23 Jan 2025 |
| Stop Loss 1 | 998.75 (-6.56%) | Price Action: 13 Nov 2024 High |
| Stop Loss 2 | 987.95 (-7.57%) | Price Action: 24 Dec 2024 High |
| Stop Loss 3 | 977.65 (-8.53%) | Price Action: 12 Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: Innova Captab is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹1073.89 serves as the nearest technical reference point.
Historical Returns: 3-month: +28.99% | 6-month: +58.48% | 1-year: +93.99%
Innova Captab Share Price Target For 2026
The line chart displays the monthly closing prices of Innova Captab with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Innova Captab shares in 2026, see the table below.
Innova Captab Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1660.22 (+55.32%) | Price Action: Chart |
| 2026 Target 2 | 1629.26 (+52.43%) | Price Action: Chart |
| 2026 Target 1 | 1613.13 (+50.92%) | Fibonacci Extension Level 64.90% |
| Current Price | 1068.85 | Innova Captab's share price as of 23 Jan 2025 |
| Stop Loss 1 | 939.64 (-12.09%) | Fibonacci Retracement Level 38.20% |
| Stop Loss 2 | 924.1 (-13.55%) | Price Action: 12 Nov 2024 Low |
| Stop Loss 3 | 913.1 (-14.58%) | Price Action: 11 Nov 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Innova Captab is currently trading near its 52-week high of ₹1260, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +93.99% | 3-year: NA | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Innova Captab Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,068.85 | ||
| 2025 | ₹1,987.84 | +85.97% | ₹2,017.66 |
| 2026 | ₹2,788.70 | +40.28% | ₹2,830.53 |
| 2027 | ₹4,449.19 | +59.54% | ₹4,515.93 |
| 2028 | ₹7,114.70 | +59.91% | ₹7,221.42 |
| 2029 | ₹10,397.57 | +46.14% | ₹10,553.53 |
| 2030 | ₹14,170.81 | +36.28% | ₹14,383.37 |
| 2031 | ₹19,156.18 | +35.18% | ₹19,443.52 |
| 2032 | ₹27,105.92 | +41.49% | ₹27,512.51 |
| 2033 | ₹39,532.55 | +45.84% | ₹40,125.54 |
| 2034 | ₹56,165.51 | +42.07% | ₹57,007.99 |
| 2035 | ₹75,047.44 | +33.61% | ₹76,173.15 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Innova Captab Brief Company Overview
Innova Captab Limited: A Comprehensive Pharmaceutical Provider Innova Captab Limited is an integrated pharmaceutical company established in 2005. Headquartered in Panchkula, India, it operates across India and internationally. The company's core business involves: ...
Research and development of pharmaceutical products Contract development and manufacturing services Distribution and marketing of generic formulation products Innova Captab's diverse product range includes: Generic formulations across various therapeutic categories Branded generic products sold through distributors, pharmacies, and e-commerce platforms The company's commitment to quality and innovation has earned it a strong reputation within the industry.Innova Captab Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 5,506.75 Crore | Market valuation of Innova Captab's shares. |
| Revenue (TTM) | 1,177.59 Crore | Total revenue generated by Innova Captab over the past twelve months. |
| Net Income (TTM) | +118.32 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +14.06% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +10.03% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+12.5% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+52.8% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
29.17 | Company's total debt divided by total shareholder equity. |
| Total Debt | 261.19 Crore | Sum of Innova Captab's current & long-term financial obligations. |
| Total Cash | 18.13 Crore | Total amount of liquid funds available to Innova Captab. |
Is Innova Captab A Good Buy For Long Term?
Innova Captab, a mid-cap stock with a market capitalization of ₹5,506.75 crore, shows mixed signals for long-term investment. While its Q2 2024-25 revenue grew by 12.5% quarter-over-quarter and profit margin stands at 10.04%, a significant debt of ₹261.19 crore against a meager cash balance of ₹18.13 crore raises concerns. Impressive short-term returns (62.58% in 3 months, 117.50% in 6 months, and 90.06% YTD) are encouraging, yet the absence of positive returns over longer periods (12 months, 3 years, 5 years) necessitates caution. Overall, it's an average buy, requiring further in-depth analysis before committing to a long-term investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
